Abstract 1688P
Background
Elderly patients are disproportionately burdened with cancer morbidity and mortality. The disease and its treatment are complicated by ageing-related issues such as loss of loved ones, socioeconomic changes, and the presence of comorbidities. Thus, they are at high risk of psychosocial distress and poor health-related quality of life. There is a significant paucity of data on the prevalence and determinants of psychosocial distress among elderly patients with cancer in Nigeria, necessitating this study.
Methods
This descriptive cross-sectional study was conducted among 296 patients aged 60 years and older with cancer attending the NSIA LUTH Cancer Centre. Data collection was interviewer-based using a structured questionnaire along with the Depression, Anxiety, and Stress Scale 21-item (DASS-21) and Functional Assessment of Chronic Illness Therapy—Spiritual Well-Being 12 (FACITsp-12). The association between different variables was assessed by chi square. Statistical analysis was done with IBM Statistical Package for Social Sciences Version 25, and a p value of <0.05 was regarded as significant.
Results
The prevalence of psychosocial distress among the respondents was depression (19.9%), anxiety (46.0%), and stress (3.0%). The majority of the respondents (77.7%) had intermediate/high spiritual levels. The prevalence of depression was significantly higher in those with comorbidities and those receiving chemotherapy. A high spiritual level was also significantly associated with a lower level of depression, anxiety, and stress.
Conclusions
We found a higher prevalence of psychosocial distress among patients who received chemotherapy as part of their treatment and also among those with comorbidities. A higher spiritual level was found to be associated with a reduced level of psychosocial distress. Therefore, there is a need to screen patients with comorbidities and those on chemotherapy for psychosocial distress in order to identify those in need of additional psychological and social work support. A holistic approach that integrates psychosocial and spiritual care into cancer treatment not only alleviates the emotional burden but also contributes to improved overall well-being and treatment outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Z. A. Ogunjimi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1709P - Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study
Presenter: Deepak Kilari
Session: Poster session 11
1710P - Exposure-response (E/R) relationship of nivolumab (N) and ipilimumab (I) in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) from the randomised phase II BIONIKK study
Presenter: Benoit Blanchet
Session: Poster session 11
1711P - Real-word data challenging the treatment paradigm in metastatic renal cancer: Time to separate IMDC intermediate / poor risk groups?
Presenter: John McGrane
Session: Poster session 11
1712P - Real-world efficacy of first-line nivolumab plus ipilimumab and its practical predictive biomarkers in advanced renal cell carcinoma: First analysis from RENOIR study [KCSG GU22-13]
Presenter: Jwa Hoon Kim
Session: Poster session 11
1713P - A deep learning approach utilizing the electronic health record (EHR) to identify cancer recurrence in renal cell carcinoma (RCC)
Presenter: Jue Hou
Session: Poster session 11
1714P - Detection and monitoring of translocation renal cell carcinoma via epigenomic profiling of cell-free DNA
Presenter: Simon Garinet
Session: Poster session 11
1715P - Interim analysis results from a phase II study of adjuvant penpulimab in very high-risk clear cell renal cell carcinoma
Presenter: Xu Zhang
Session: Poster session 11
1716P - Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1)
Presenter: martina catalano
Session: Poster session 11